Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03785197
Other study ID # FASTA
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date February 1, 2018
Est. completion date March 1, 2022

Study information

Verified date May 2021
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is a scientific and prospective documentation of the clinical effects of an inpatient treatment at the Immanuel Hospital of Berlin, in the department for complementary and integrative medicine, with the use of a modified fasting regime. A pre- and post- as well as group comparisons are planned. Patients that are admitted to the inpatient department for metabolic syndrome, osteoarthritis of the hip or knee, rheumatoid arthritis and fibromyalgia will be enrolled in the study.


Description:

At the beginning, during and at the end of the treatment at the inpatient department routine blood parameters, anthropometric parameters and certain scores and parameters specific to the different conditions will be measured. Questionnaires will be filled out by patients before and after the treatment as well as 3, 6 and 12 months after leaving the inpatient department.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 500
Est. completion date March 1, 2022
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - The patient is consents to participating in the trial during the first 24h of his or her stay in the inpatient naturopathic department of the Immanuel Hospital. - Written informed consent is given - The referral diagnosis is one of the following: diabetes mellitus type 2/metabolic syndrome, osteoarthritis of the hip, osteoarthritis of the knee, rheumatoid arthritis, fibromyalgia. Exclusion Criteria: - Language barries to understanding the instructions of the study personnel - Dementia or other strong cognitive impairment - Pregnant or lactating women - Taking part in another study at the same time

Study Design


Intervention

Other:
Prolonged modified fasting
The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths

Locations

Country Name City State
Germany Immanuel Hospital Berlin-Wannsee Berlin

Sponsors (1)

Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fibromyalgia Impact Questionnaire (FIQ) Questionnaire; The FIQ is scored in such a way that a higher score indicates a greater impact of the syndrome on the person. Each of the 10 items has a maximum possible score of 10. Thus the maximum possible score is 100. The average FM patient scores about 50, severely afflicted patients are usually 70 plus. Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Primary Disease Activity Score 28 (DAS 28) Questionnaire with Clinical Examination; Change from Baseline in the DAS-28, range from 2.0 to 10.0 while higher values meaning a higher disease activity and below of 2.6 meaning remission Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Primary Health Assessment Questionnaire (HAQ) Questionnaire; Change from Baseline in the HAQ, range from 0 to 3 while higher values meaning a higher grade of disability Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Primary Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Questionnaire consisting of 24 items divided into 3 subscales: Pain (5items), Stiffness (2 items), Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).
The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. Higher values meaning a higher grade of disability.
Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Primary Summary of Diabetes Self Care Activities Measure (SDSCA) Questionnaire; 11 items with each item scored on a scale of 0-7. Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Secondary Pain on Visual Analogue Scale (VAS) Questionnaire Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Secondary Hospital Anxiety and Depression Scale (HADS) Questionnaire; HADS: Assessing full scale, range 0-42, lower score meaning a better outcome Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Secondary Perceived Stress Scale (PSS) Questionnaire; Change from Baseline in the PSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 & 4 = 0) to the positively stated items and then summing across all scale items while higher values meaning a higher grade of perceived stress. Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Secondary Quality of Life (WHO-5) Questionnaire; Change from Baseline in the WHO-5, range from 0 to 100 % while higher values meaning a higher grade of well-being Change Baseline, 2 weeks, 3 months, 6 months, 12 months
Secondary Body-Mass-Index (BMI) Anthropometry Change Baseline, 2 weeks
Secondary Blood pressure Measuring systolic and diastolic blood pressure in mmHg Change Baseline, 2 weeks
Secondary 24h-Blood pressure Measuring systolic and diastolic blood pressure with Device "Mobil-O-Graph" Change Baseline, 2 weeks
Secondary Blood count Laboratory test Change Baseline, 2 weeks
Secondary Glomerular filtration rate (GFR) Laboratory test Change Baseline, 2 weeks
Secondary Blood lipids triglycerides (mmol/L), total cholesterol (mmol/L), LDL (mmol/L), HDL (mmol/L), fasting glucose (mmol/L) Change Baseline, 2 weeks
Secondary CRP CRP in milligram per liter (mg/L) Change Baseline, 2 weeks
Secondary Liver enzymes (GOT, GPT) Hepatic transaminases (GPT, GOT in U/L) Change Baseline, 2 weeks
Secondary Stepcounter With Device "Everion" Change Baseline, 2 weeks
Secondary Heart Rate Variability With Device "Faros 180" Change Baseline, 2 weeks
Secondary Heart Rate With Device "Everion" Change Baseline, 2 weeks
Secondary Blood Oxygenation With Device "Everion" Change Baseline, 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4